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Editorial
Poor quality research and clinical 
practice during COVID-19
The COVID-19 pandemic has turned our lives 
upside down. Health services have adapted to 
the challenges posed by the pandemic at eye-
watering speed. Telemedicine has seen a rapid 
uptake in order for patient–physician encounters 
to comply with social distancing regulations. 
Elective surgeries have been put on hold to make 
room in hospitals for patients with COVID-19 and 
save valuable personal protective equipment. Many 
pre-pandemic research projects have been put on 
hold, and legions of medical researchers are now 
dedicated to researching COVID-19.
The number of publications on COVID-19, many 
published on pre-print servers that allow sharing of 
a research publicly before it has been peer reviewed, 
is skyrocketing. Many journals have seen a drastic 
increase in manuscript submissions. The demand 
for quick distribution of information on a disease 
that we still know very little about is understandable 
and justified, and rapid dissemination of knowledge 
that can be accessed freely without a paywall is 
desirable. COVID-19, however, also highlights and 
amplifies some of the challenges clinical research 
and practice are facing in general.
Studies published on pre-print servers before peer 
review allow unrestricted and quick access to research 
results. There is, however, a significant danger that 
flawed results are picked up and disseminated by the 
media [1]. Studies with positive results, indicating 
effectiveness of an intervention, are likely to receive 
more attention than studies with negative results, 
even if the latter are of higher quality.
There are numerous trials on different drug 
interventions competing for the same pool of 
COVID-19 patients, many with poor study design 
(e.g. small sample size, no comparator group, not 
randomised, single centre and no study protocol 
publicly available) [1]. Trying to draw conclusions 
about the effectiveness of interventions based on 
(biased) nonrandomised studies can be grossly 
misleading. In the rush to make the latest science 
available, editorial scrutiny may fall short of usual 
benchmarks, as evidenced by the publication of 
large numbers of poorly designed studies, but also 
poor editing including increases in clunky, awkward 
or otherwise poor phrasing, grammatical errors, and 
mislabelling of tables and figures.
Some COVID-19 investigators have never 
conducted research in patients with respiratory 
infections before and are not embedded in 
research networks with the required expertise 
to deliver high-quality trials. This will likely lead 
to wasteful, poor-quality research. National 
research funding bodies in most countries have 
missed the opportunity to streamline research 
efforts and focus on a small number of large, 
high-quality trials supported by extensive clinical 
research networks rather than a large number of 
small (and likely underpowered) studies. During 
any pandemic, evidence is rapidly developing and 
treatments might no longer be of interest by the 
time a trial starts recruiting patients. Bayesian 
adaptive trial designs are therefore particularly 
suited to these circumstances. They will allow us 
to assess the most promising treatments based on 
the state of knowledge at the time and will increase 
the probability of patients being randomised to the 
best-performing treatments [2].
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There is a substantial imbalance in trial topics 
with only a small proportion of COVID-19 trials 
registered on ClinicalTrials.gov focusing on non-
drug interventions [1]. This pertains to important 
preventive non-drug interventions, such as hand 
hygiene and wearing of masks, but also non-drug 
interventions to treat patients with COVID-19, 
such as noninvasive positive pressure ventilation 
(NIPPV). The use of NIPPV is discouraged in some 
settings in favour of early intubation to minimise 
viral aerosolisation (and therefore the risk of viral 
transmission to healthcare workers). It is, however, 
unknown whether the use of NIPPV is associated 
with increased viral aerosolisation and transmission 
compared with oxygen therapy delivered via 
nasal prongs, Hudson mask or high-flow nasal 
cannula. Patients who overcome COVID-19 with 
NIPPV as opposed to intubation will likely make 
a quicker recovery, but it is unknown whether 
delayed intubation in patients with COVID-19 in 
whom NIPPV fails is associated with a higher risk 
of complications. On 17 May 2020, 1528 studies 
were registered on ClinicalTrials.gov using the term 
“COVID”, of which only three were randomised 
trials to assess NIPPV, despite the urgent need for 
evidence to inform clinical practice in this area.
Physicians are frequently using experimental 
therapies in critically ill patients with COVID-19 in 
the absence of proven effective treatments. They 
may, however, significantly underestimate potential 
harms of these drugs, for example, the potential 
cardiotoxicity of hydroxychloroquine, ritonavir, 
lopinavir, interferon-α2β, azithromycin and 
methylprednisolone [3]. Clinicians must resist the 
impulse “to do something” and only use unproven 
treatments within clinical (ideally adaptive) trials 
[3]. The tendency to prefer action over inaction is 
also known as commission bias and is motivated by 
avoiding regret about a missed opportunity when a 
treatment is not given, even if its efficacy is unclear 
[4]. Commission bias is a potential barrier to the 
implementation of evidence-based practice, and 
drives overtreatment and “low-value care” (care that 
provides little or no benefit and may cause harm 
to patients) [4]. As clinicians, we must reflect on 
the biases that may influence our clinical decision-
making, critically appraise the evidence of COVID-19 
treatments, and act with caution and reason [5].
There might be exceptions to the rule, especially 
for non-drug interventions, where the use of the 
“precautionary principle” is sensible. This principle 
is a strategy to “adopt precautionary measures 
when scientific evidence about an environmental 
or human health hazard is uncertain and the stakes 
are high” [6]. It has been proposed that this principle 
should be applied to the wearing of face masks in 
public, because COVID-19 is a serious threat and 
the potential benefits of wearing a mask likely 
outweigh potential downsides, including a false 
sense of security and reduced compliance with 
other infection control measures [7]. In a similar 
way, the precautionary principle should be applied 
to hand hygiene to reduce the spread of coronavirus.
It is likely that COVID-19 will pose a challenge to 
our healthcare systems for the foreseeable future, 
and we will have to find ways to treat patients with 
COVID-19 while not neglecting patients with other 
diseases. With this in mind, I hope that the June 
issue of Breathe on the topic of “Rare and orphan 
lung diseases” will be informative and inspirational.
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